Neil Kumar insider trades

Open-market stock purchases and sales by Neil Kumar, Chief Executive Officer at BridgeBio Pharma, Inc, from SEC Form 4 filings since Jun 22, 2018.

Recent trades

DateStockTradeValue
Sep 17, 2026BBIO BridgeBio Pharma, IncSold$602K
Sep 17, 2026BBIO BridgeBio Pharma, IncSold$89K
Aug 19, 2026BBIO BridgeBio Pharma, IncSold$679K
Aug 19, 2026BBIO BridgeBio Pharma, IncSold$152K
Aug 19, 2026BBIO BridgeBio Pharma, IncSold$8.6K
Aug 18, 2026BBIO BridgeBio Pharma, IncSold$154K
Aug 18, 2026BBIO BridgeBio Pharma, IncSold$1.4M
Aug 18, 2026BBIO BridgeBio Pharma, IncSold$1.2M
Aug 18, 2026BBIO BridgeBio Pharma, IncSold$100K
Aug 16, 2026BBIO BridgeBio Pharma, IncBought (not open market)—
Aug 16, 2026BBIO BridgeBio Pharma, IncBought (not open market)—
Aug 16, 2026BBIO BridgeBio Pharma, IncBought (not open market)—
Aug 16, 2026BBIO BridgeBio Pharma, IncBought (not open market)—
Aug 16, 2026BBIO BridgeBio Pharma, IncSold (not open market)$2.9M
Aug 16, 2026BBIO BridgeBio Pharma, IncBought (not open market)—
Aug 16, 2026BBIO BridgeBio Pharma, IncBought (not open market)—
Aug 16, 2026BBIO BridgeBio Pharma, IncBought (not open market)—
Aug 16, 2026BBIO BridgeBio Pharma, IncBought (not open market)—
Jun 16, 2026BBOT BridgeBio Oncology Therapeutics, IncBought (not open market)—
Jun 5, 2026BBIO BridgeBio Pharma, IncSold$480K
Jun 5, 2026BBIO BridgeBio Pharma, IncSold$305K
Jun 5, 2026BBIO BridgeBio Pharma, IncSold$480K
Jun 5, 2026BBIO BridgeBio Pharma, IncSold$573K
Jun 5, 2026BBIO BridgeBio Pharma, IncSold$304K
Jun 4, 2026BBIO BridgeBio Pharma, IncSold$145K

Companies traded

  • BBIO BridgeBio Pharma, Inc: 198 sales, last Sep 17, 2026
  • BBOT BridgeBio Oncology Therapeutics, Inc: other filings, last Jun 16, 2026
  • MAZE Maze Therapeutics, Inc: other filings, last Mar 27, 2026
  • EIDX Eidos Therapeutics, Inc: 3 buys, last Jul 3, 2019

Get free alerts when Neil Kumar files a new trade →